Credit Suisse’s Vigil Neuroscience VIGL Stock Holding History

Credit Suisse’s Portfolio VIGL Stock Details VIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4	Closed	–	–	4316
2022 Q2	$0	Buy	+4	New	+$16	﹤0.01%	4347

Other funds holding VIGL

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Credit Suisse's VIGL Position: Q3 2022 in Review

Credit Suisse sold out of Vigil Neuroscience (VIGL) in Q3 2022, closing a stake of 4 shares.

Credit Suisse first reported a position in VIGL in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 33 funds tracked by Wall St. Rank hold VIGL as of Q3 2022.

Credit Suisse reported no remaining Vigil Neuroscience position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 4 Vigil Neuroscience shares in Q3 2022.
Credit Suisse first reported a position in Vigil Neuroscience in Q2 2022 and held it in 1 quarter.
Credit Suisse's Vigil Neuroscience position peaked at $0 in Q2 2022.
33 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.